| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma EA Olsen, YH Kim, TM Kuzel, TR Pacheco, FM Foss, S Parker, SR Frankel, ... Journal of clinical oncology 25 (21), 3109-3115, 2007 | 1205 | 2007 |
| Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ... Clinical cancer research 21 (19), 4286-4293, 2015 | 771 | 2015 |
| The impact of serum uric acid on cardiovascular outcomes in the LIFE study A Høieggen, MH Alderman, SE Kjeldsen, S Julius, RB Devereux, ... Kidney international 65 (3), 1041-1049, 2004 | 738 | 2004 |
| Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes G Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, ... Blood, The Journal of the American Society of Hematology 111 (3), 1060-1066, 2008 | 529 | 2008 |
| Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects CA Guzzo, CI Furtek, AG Porras, C Chen, R Tipping, CM Clineschmidt, ... The Journal of Clinical Pharmacology 42 (10), 1122-1133, 2002 | 468 | 2002 |
| Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ... Journal of clinical oncology 30 (19), 2307-2313, 2012 | 343 | 2012 |
| Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer J Vansteenkiste, E Van Cutsem, H Dumez, C Chen, JL Ricker, ... Investigational new drugs 26, 483-488, 2008 | 199 | 2008 |
| Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer GR Blumenschein, MS Kies, VA Papadimitrakopoulou, C Lu, AJ Kumar, ... Investigational new drugs 26, 81-87, 2008 | 196 | 2008 |
| Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma M Duvic, EA Olsen, D Breneman, TR Pacheco, S Parker, EC Vonderheid, ... Clinical Lymphoma and Myeloma 9 (6), 412-416, 2009 | 131 | 2009 |
| A cohort autopsy study defines COVID-19 systemic pathogenesis XH Yao, T Luo, Y Shi, ZC He, R Tang, PP Zhang, J Cai, XD Zhou, ... Cell research 31 (8), 836-846, 2021 | 126 | 2021 |
| Integrating predictive biomarkers and classifiers into oncology clinical development programmes RA Beckman, J Clark, C Chen Nature reviews Drug discovery 10 (10), 735-748, 2011 | 125 | 2011 |
| Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. A Patnaik, SP Kang, AW Tolcher, DW Rasco, KP Papadopoulos, ... Journal of Clinical Oncology 30 (15_suppl), 2512-2512, 2012 | 109 | 2012 |
| Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic SP Kang, K Gergich, GM Lubiniecki, DP de Alwis, C Chen, MAB Tice, ... Annals of Oncology 28 (6), 1388-1398, 2017 | 93 | 2017 |
| An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice TL Meinking, CM Clineschmidt, C Chen, MA Kolber, RW Tipping, ... The Journal of pediatrics 141 (5), 665-670, 2002 | 83 | 2002 |
| Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker RA Beckman, Z Antonijevic, R Kalamegham, C Chen Clinical Pharmacology & Therapeutics 100 (6), 617-625, 2016 | 78 | 2016 |
| A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors K Holen, R DiPaola, G Liu, AR Tan, G Wilding, K Hsu, N Agrawal, C Chen, ... Investigational new drugs 30, 1088-1095, 2012 | 66 | 2012 |
| Statistical design and considerations of a phase 3 basket trial for simultaneous investigation of multiple tumor types in one study C Chen, X Li, S Yuan, Z Antonijevic, R Kalamegham, RA Beckman Statistics in Biopharmaceutical Research 8 (3), 248-257, 2016 | 61 | 2016 |
| Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group AM Stone, W Bushnell, J Denne, DJ Sargent, O Amit, C Chen, ... European Journal of Cancer 47 (12), 1763-1771, 2011 | 56 | 2011 |
| Optimal cost-effective designs of phase II proof of concept trials and associated go–no go decisions C Chen, RA Beckman∗ Journal of Biopharmaceutical Statistics 19 (3), 424-436, 2009 | 56 | 2009 |
| Proportion of treatment effect (PTE) explained by a surrogate marker C Chen, H Wang, SM Snapinn Statistics in medicine 22 (22), 3449-3459, 2003 | 52 | 2003 |
